Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;22(4):358-368.
doi: 10.5223/pghn.2019.22.4.358. Epub 2019 Jun 25.

Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease

Min Hyung Woo  1 , Young Hoon Cho  1 , Min Ji Sohn  1 , Eun Joo Lee  1 , Ju Whi Kim  1 , Jin Soo Moon  1 , Jae Sung Ko  1 , Hyun-Young Kim  2
Affiliations

Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease

Min Hyung Woo et al. Pediatr Gastroenterol Hepatol Nutr. 2019 Jul.

Abstract

Purpose: Pediatric Crohn's disease (CD) is directly related to growth and has a high probability of requiring surgical intervention(s); therefore, more active treatment for CD is required for children. This study investigated the impact of biologics on growth and disease course associated with surgery.

Methods: This was a retrospective cohort study involving patients diagnosed with CD at the Seoul National University Children's Hospital (Seoul, Korea) between January 2006 and October 2017. The aim was to determine the characteristics of pediatric patients with CD and whether biologics affected growth and the surgical disease course.

Results: Among patients who underwent surgery for CD, the mean number of operations per patient was 1.89. The mean time from initial diagnosis to surgery was 19.3 months. The most common procedure was fistulectomy (34%), followed by incision and drainage (25%). In all patients, the use of biologics increased the height (p=0.002) and body mass index (BMI) (p=0.005). Among patients who underwent surgery, height (p=0.004) and BMI (p=0.048) were increased in the group using biologics. Patients who used biologics exhibited a low operation rate only within 2 years after diagnosis, with no differences thereafter (p=0.027).

Conclusion: Although biologics could not mitigate the operation rate in pediatric patients who underwent surgery for CD, biological therapy delayed disease progression within 2 years of disease onset. Additionally, biologics conferred growth and BMI benefits in this window period. Therefore, it may be helpful to use biologics for optimal growth in pediatric patients with a high probability of undergoing future surgery.

Keywords: Children; Crohn's disease; Growth; Infliximab; Surgery.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no financial conflicts of interest.

Figures

Fig. 1
Fig. 1. Frequency of procedure types in pediatric Crohn's disease. The most common operation was fistulectomy (34%), followed by incision and drainage (I&D) (25%), small bowel resection (15%), right hemicolectomy (11%), ileocolectomy (9%), and total colectomy (5%).
I&D: incision and drainage.
Fig. 2
Fig. 2. Box and Whisker plots of differences in height and BMI z-scores from diagnosis to follow-up according to the use of biologics. Height and BMI z-scores from diagnosis to October 2017 according to the use of biologics in all patients (A); in total operated patients (B); in perianal lesion operated patients (C); in non-perianal lesion operated patients (D); and in non-operated patients (E).
BMI: body mass index.
Fig. 3
Fig. 3. Cumulative operation rate in the operation group. Kaplan-Meier statistics comparing the duration from diagnosis to operation according to the use of biologics. Cumulative operation rates are shown in all patients (A); in all patients in the operation group (B); in the perianal lesion operated group (C); and in the non-perianal lesion operated group (D).
See this image and copyright information in PMC

References

    1. Lee YJ, Oh SH, Kim KM. The principles of drug therapy of Crohn's disease in child and adolescent. Korean J Pediatr Gastroenterol Nutr. 2010;13:S59–69.
    1. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui A, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013;145:158–165.e2. - PubMed
    1. Polito JM, 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580–586. - PubMed
    1. Cuffari C, Dubinsky M, Darbari A, Sena L, Baldassano R. Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management. Inflamm Bowel Dis. 2005;11:696–704. - PubMed
    1. Lee YA, Chun P, Hwang EH, Mun SW, Lee YJ, Park JH. Clinical features and extraintestinal manifestations of Crohn disease in children. Pediatr Gastroenterol Hepatol Nutr. 2016;19:236–242. - PMC - PubMed